Literature DB >> 4439889

Pseudomembranous enterocolitis. Resurgence related to newer antibiotic therapy.

E B Keeffe, R M Katon, T T Chan, C S Melnyk, J A Benson.   

Abstract

Six patients with pseudomembranous entercolitis were seen at one institution over a six-month period. Clindamycin therapy preceded the diagnosis in all six patients and possibly caused the disease in five cases. Common clinical features included diarrhea, abdominal pain, fever, leukocytosis, radiographic findings of large bowel dilatation with mucosal thickening and a characteristic sigmoidoscopic or gross pathologic demonstration of discrete yellow-white plaques on an otherwise normal mucosa. Complications included toxic megacolon and sigmoid colon perforation. Two of the six patients died. The literature since 1970 is tabulated to clarify the clinical and pathological features of pseudomembranous enterocolitis associated with newer antibiotic therapy. Lincomycin and clindamycin are strongly implicated in the recent resurgence of this formerly rare variety of colitis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4439889      PMCID: PMC1129645     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  28 in total

1.  Pseudomembranous enterocolitis. A clinicopathologic study.

Authors:  D BIRNBAUM; A LAUFER; M FREUND
Journal:  Gastroenterology       Date:  1961-10       Impact factor: 22.682

2.  Pseudomembranous colitis following aureomycin and chloramphenicol.

Authors:  L REINER; M J SCHLESINGER; G M MILLER
Journal:  AMA Arch Pathol       Date:  1952-07

3.  Pseudomembraneous enterocolitis--an unwelcome gastrointestinal complication of antibiotic therapy.

Authors:  J A Ecker; R G Williams; J E McKittrick; R M Failing
Journal:  Am J Gastroenterol       Date:  1970-09       Impact factor: 10.864

4.  Acute enterocolitis. A complication of antibiotic therapy.

Authors:  R L Schapiro; A Newman
Journal:  Radiology       Date:  1973-08       Impact factor: 11.105

5.  A reappearance of antibiotic-induced pseudomembranous enterocolitis.

Authors:  T E Tully; S B Feinberg
Journal:  Radiology       Date:  1974-03       Impact factor: 11.105

6.  Clindamycin-associated colitis.

Authors:  L E Cohen; C J McNeill; R F Wells
Journal:  JAMA       Date:  1973-03-19       Impact factor: 56.272

7.  Colitis following oral lincomycin therapy.

Authors:  F E Pittman; J C Pittman; C D Humphrey
Journal:  Arch Intern Med       Date:  1974-08

8.  Diagnostic features of clindamycin-associated pseudomembranous colitis.

Authors:  F J Tedesco; R J Stanley; D H Alpers
Journal:  N Engl J Med       Date:  1974-04-11       Impact factor: 91.245

9.  Nonspecific colitis following oral lincomycin therapy.

Authors:  G B Manashil; J A Kern
Journal:  Am J Gastroenterol       Date:  1973-10       Impact factor: 10.864

Review 10.  Lincomycin.

Authors:  K Kaplan; L Weinstein
Journal:  Pediatr Clin North Am       Date:  1968-02       Impact factor: 3.278

View more
  6 in total

1.  Infectious disease emergencies. Part IV: Patients presenting with gastrointestinal disorders.

Authors:  P A Oill
Journal:  West J Med       Date:  1977-01

2.  Antimicrobial agent-associated colitis and diarrhea.

Authors:  W L George
Journal:  West J Med       Date:  1980-08

3.  Pneumoperitoneum without faecal peritonitis in a patient with pseudomembranous colitis.

Authors:  D Klinger; P Radford; J Callin
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-28

4.  Clindamycin-associated colitis. Review of the clinical spectrum of 47 cases.

Authors:  F J Tedesco
Journal:  Am J Dig Dis       Date:  1976-01

5.  Corticosteroids in the Treatment of Pseudomembranous Colitis: A Report of 3 Cases.

Authors:  Ella Sykes; Patrick McDonald; Paul K Flanagan
Journal:  Gastroenterology Res       Date:  2012-09-20

6.  In vitro susceptibility of common clinical anaerobic and aerobic isolates against josamycin.

Authors:  R E Reese; R F Betts; L W Goedde; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.